GlassScriptPhysician profile
Ronald K Hsu
NPI 1700912318
$132,270.21
in general payments reported to CMS, 2019-2025
33 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,846 · 2020: $503 · 2021: $5,613 · 2022: $23K · 2023: $47K · 2024: $27K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $16K · Food and Beverage: $5,917 · Consulting Fee: $4,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,600.00 |
| Travel and Lodging | $15,888.69 |
| Food and Beverage | $5,917.40 |
| Consulting Fee | $4,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117,445.65 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $5,556.41 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $4,913.60 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.46 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $425.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.39 | 2019-2023 | Gattex, Entyvio |
| Janssen Biotech, INC. | $384.18 | 2019-2025 | Tremfya, Stelara |
| Cook Medical LLC | $300.00 | 2019 | |
| Celgene Corporation | $294.55 | 2019-2023 | Zeposia |
| Genzyme Corporation | $268.58 | 2023-2025 | |
| Gilead Sciences, INC. | $265.01 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $236.50 | 2019-2023 | Dificid |
| Qol Medical, LLC | $189.82 | 2019-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $130.18 | 2019-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $127.42 | 2025 | Vowst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Romark Laboratories, Lc | $123.65 | 2019 | |
| Ardelyx, INC. | $94.94 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $83.56 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $63.43 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $62.76 | 2025 | Voquezna |
| Celltrion USA INC. | $46.89 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $44.04 | 2019 | |
| Ucb, INC. | $40.59 | 2019 | |
| Daiichi Sankyo INC. | $39.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.80 | 2023 | Dupixent |
| Alfasigma USA, INC. | $28.66 | 2020 | |
| Lilly USA, LLC | $19.13 | 2025 | Omvoh |
| Novo Nordisk INC | $18.44 | 2025 | Wegovy |
| Capsovision, INC. | $15.32 | 2025 | Capsocam Plus |
| Olympus America INC. | $15.07 | 2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Covidien LP | $12.07 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.